Genfit S.A. (GNFT) - Net Assets
Based on the latest financial reports, Genfit S.A. (GNFT) has net assets worth €-23.64 Million EUR (≈ $-27.64 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€157.93 Million ≈ $184.64 Million USD) and total liabilities (€181.58 Million ≈ $212.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Genfit S.A. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-23.64 Million |
| % of Total Assets | -14.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -119.85% |
| 10-Year Change | -116.56% |
| Growth Volatility | 125.99 |
Genfit S.A. - Net Assets Trend (2003–2025)
This chart illustrates how Genfit S.A.'s net assets have evolved over time, based on quarterly financial data. See GNFT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Genfit S.A. (2003–2025)
The table below shows the annual net assets of Genfit S.A. from 2003 to 2025. For live valuation and market cap data, see Genfit S.A. (GNFT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-23.64 Million ≈ $-27.64 Million |
-134.16% |
| 2024-12-31 | €69.22 Million ≈ $80.93 Million |
+1.87% |
| 2023-12-31 | €67.95 Million ≈ $79.44 Million |
-28.12% |
| 2022-12-31 | €94.53 Million ≈ $110.51 Million |
-20.63% |
| 2021-12-31 | €119.10 Million ≈ $139.24 Million |
+836.90% |
| 2020-12-31 | €-16.16 Million ≈ $-18.90 Million |
-119.23% |
| 2019-12-31 | €84.06 Million ≈ $98.28 Million |
+301.48% |
| 2018-12-31 | €20.94 Million ≈ $24.48 Million |
-79.91% |
| 2017-12-31 | €104.23 Million ≈ $121.85 Million |
-27.01% |
| 2016-12-31 | €142.80 Million ≈ $166.94 Million |
+157.68% |
| 2015-12-31 | €55.42 Million ≈ $64.79 Million |
-21.32% |
| 2014-12-31 | €70.43 Million ≈ $82.34 Million |
+399.74% |
| 2013-12-31 | €14.09 Million ≈ $16.48 Million |
+106.22% |
| 2012-12-31 | €6.83 Million ≈ $7.99 Million |
+53.33% |
| 2011-12-31 | €4.46 Million ≈ $5.21 Million |
-46.87% |
| 2010-12-31 | €8.39 Million ≈ $9.81 Million |
-45.95% |
| 2009-12-31 | €15.52 Million ≈ $18.14 Million |
-30.66% |
| 2008-12-31 | €22.38 Million ≈ $26.17 Million |
-11.77% |
| 2007-12-31 | €25.37 Million ≈ $29.66 Million |
-8.65% |
| 2006-12-31 | €27.77 Million ≈ $32.47 Million |
+107.45% |
| 2005-12-31 | €13.39 Million ≈ $15.65 Million |
-4.37% |
| 2004-12-31 | €14.00 Million ≈ $16.37 Million |
+54.76% |
| 2003-12-31 | €9.04 Million ≈ $10.57 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genfit S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18526.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €12.51 Million | % |
| Other Comprehensive Income | €433.00K | % |
| Other Components | €438.80 Million | % |
| Total Equity | €-23.64 Million | 100.00% |
Genfit S.A. Competitors by Market Cap
The table below lists competitors of Genfit S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Univanich Palm Oil Public Company Limited
BK:UVAN
|
$424.84 Million |
|
Jiangnan Yifan Motor Co.Ltd
SHE:301023
|
$424.97 Million |
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
$425.12 Million |
|
QingCloud Technologies Corp.
SHG:688316
|
$425.17 Million |
|
Raymond Limited
NSE:RAYMOND
|
$424.71 Million |
|
LX Holdings Corp
KO:383800
|
$424.67 Million |
|
Plasson Indus
TA:PLSN
|
$424.67 Million |
|
Shanghai Xujiahui Commercial Co Ltd
SHE:002561
|
$424.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genfit S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 69,224,000 to -23,645,000, a change of -92,869,000 (-134.2%).
- Net loss of 85,968,000 reduced equity.
- Share repurchases of 51,000 reduced equity.
- New share issuances of 51,000 increased equity.
- Other comprehensive income increased equity by 86,000.
- Other factors decreased equity by 6,987,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-85.97 Million | -363.58% |
| Share Repurchases | €51.00K | -0.22% |
| Share Issuances | €51.00K | +0.22% |
| Other Comprehensive Income | €86.00K | +0.36% |
| Other Changes | €-6.99 Million | -29.55% |
| Total Change | €- | -134.16% |
Book Value vs Market Value Analysis
This analysis compares Genfit S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €1.15 | €9.48 | x |
| 2005-12-31 | €1.15 | €9.48 | x |
| 2006-12-31 | €2.39 | €9.48 | x |
| 2007-12-31 | €2.18 | €9.48 | x |
| 2008-12-31 | €1.93 | €9.48 | x |
| 2009-12-31 | €1.34 | €9.48 | x |
| 2010-12-31 | €0.70 | €9.48 | x |
| 2011-12-31 | €0.35 | €9.48 | x |
| 2012-12-31 | €0.45 | €9.48 | x |
| 2013-12-31 | €0.70 | €9.48 | x |
| 2014-12-31 | €3.07 | €9.48 | x |
| 2015-12-31 | €2.24 | €9.48 | x |
| 2016-12-31 | €5.32 | €9.48 | x |
| 2017-12-31 | €3.34 | €9.48 | x |
| 2018-12-31 | €0.67 | €9.48 | x |
| 2019-12-31 | €2.27 | €9.48 | x |
| 2020-12-31 | €-0.42 | €9.48 | x |
| 2021-12-31 | €2.14 | €9.48 | x |
| 2022-12-31 | €1.90 | €9.48 | x |
| 2023-12-31 | €1.37 | €9.48 | x |
| 2024-12-31 | €1.38 | €9.48 | x |
| 2025-12-31 | €-0.47 | €9.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genfit S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -131.38%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 29.12% | 23.85% | 0.41x | 2.95x | €1.69 Million |
| 2004 | 18.65% | 17.33% | 0.41x | 2.65x | €997.54K |
| 2005 | 13.29% | 13.88% | 0.41x | 2.31x | €438.76K |
| 2006 | 1.18% | 3.26% | 0.22x | 1.67x | €-2.45 Million |
| 2007 | -11.04% | -29.55% | 0.24x | 1.59x | €-5.34 Million |
| 2008 | -17.70% | -45.21% | 0.19x | 2.05x | €-6.20 Million |
| 2009 | -47.51% | -126.87% | 0.15x | 2.48x | €-8.93 Million |
| 2010 | -111.82% | -249.65% | 0.12x | 3.74x | €-10.22 Million |
| 2011 | -217.22% | -410.09% | 0.08x | 6.52x | €-10.13 Million |
| 2012 | -79.19% | -323.60% | 0.07x | 3.45x | €-6.09 Million |
| 2013 | -89.78% | -666.15% | 0.07x | 2.07x | €-14.06 Million |
| 2014 | -24.17% | -1054.60% | 0.02x | 1.23x | €-24.07 Million |
| 2015 | -30.92% | -3251.42% | 0.01x | 1.25x | €-22.68 Million |
| 2016 | -23.58% | -11854.58% | 0.00x | 1.16x | €-47.95 Million |
| 2017 | -56.23% | -49664.41% | 0.00x | 2.81x | €-69.03 Million |
| 2018 | -379.77% | -115247.83% | 0.00x | 10.96x | €-81.61 Million |
| 2019 | -77.49% | -211.24% | 0.10x | 3.69x | €-73.55 Million |
| 2020 | 0.00% | -13231.50% | 0.00x | 0.00x | €-99.60 Million |
| 2021 | 56.47% | 84.00% | 0.28x | 2.37x | €55.35 Million |
| 2022 | -25.09% | -117.45% | 0.09x | 2.28x | €-33.17 Million |
| 2023 | -42.52% | -101.15% | 0.16x | 2.56x | €-35.69 Million |
| 2024 | 2.18% | 2.25% | 0.44x | 2.19x | €-5.42 Million |
| 2025 | 0.00% | -131.38% | 0.41x | 0.00x | €-83.60 Million |
Industry Comparison
This section compares Genfit S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $33,345,754
- Average return on equity (ROE) among peers: -383.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genfit S.A. (GNFT) | €-23.64 Million | 29.12% | N/A | $424.82 Million |
| Abionyx Pharma SA (ABNX) | $6.67 Million | 27.74% | 0.54x | $104.56 Million |
| Abivax SA (ABVX) | $1.88 Million | -3227.42% | 37.98x | $7.75 Billion |
| Adocia (ADOC) | $42.76 Million | -18.46% | 0.84x | $93.64 Million |
| Aelis Farma SA (AELIS) | $-710.00K | 0.00% | 0.00x | $17.24 Million |
| Biophytis S.A. (ALBPS) | $5.71 Million | -587.66% | 5.36x | $752.91K |
| Cellectis (ALCLS) | $274.05 Million | -23.32% | 0.21x | $228.29 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $18.78 Million |
| Genoway (ALGEN) | $5.10 Million | 5.12% | 0.91x | $31.09 Million |
| Integragen (ALINT) | $1.76 Million | -14.58% | 2.14x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.08 Million | 0.00% | 0.00x | $1.80 Million |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more